More papers that ARE being presented at ASCO (group 5)


The following report gives core information on a fifth group of 15 papers that are being formally presented at ASCO. Again, we have highlighted the names of the authors and the titles of the papers that look to be of particular interest:

  • Pinski et al. (“SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 [IL-6], in chemotherapy pretreated patients [pts] with castration- resistant prostate cancer [CRPC]”) have reported data suggesting that CNTO0328 has biologic activity but limited effectiveness in the treatment of men with chemotherapy-resistant CRPC.
  • Mohebtash et al. (“Phase I trial of targeted therapy with PSA-TRICOM vaccine [V] and ipilimumab [ipi] in patients [pts] with metastatic castration-resistant prostate cancer [mCRPC]”) have reported very early clinical data on the potential of the PSA-TRICOM “vaccine” with ipilimumab in men with metastatic CPRC.
  • Medioni et al. (“Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer [HRPC] patients”) have reported Phase I data on the combination of inecalcitol + docetaxel + prednisone in men with HRPC.
  • Gross et al. (“Phase I trial of RAD001 [R], bevacizumab [B], and docetaxel [D] for castration-resistant prostate cancer [CRPC]”) have reported Phase I data on the combination of RAD001 + bevacizumab + docetaxel in men with CRPC.
  • Lachey et al. (“Effect of a soluble activin receptor type IIB on androgen-deprivation-induced effects on body composition”) report that RAP-031 may be able to offset negative side effects of ADT and have other significant therapeutic implications for prostate cancer patients needing hormone therapy.
  • De Jager et al. (“Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer [CRPC]“) report Phase II data from use of a combination of picoplatin + dfocetaxel + prednisone in treatment of men with CRPC.
  • Petrylak et al. (“A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer”) report data from an open-label trial of docetaxel + lenalidomide in men with CRPC.
  • Trock et al. (“Survival following early hormone therapy for men with rapid PSA doubling time within 2 years following radical prostatectomy”) report that early salvage hormonal therapy may significantly and substantially prolong overall survival in men who have early biochemical recurrence with a rapid PSA doubling time.
  • Snyder et al. (“Costs of treatments for local/regional prostate cancer”) have assessed the costs of differing types of treatment for localized and regionally advanced prostate cancer.
  • Eisinger et al. (“Trends in screening for prostate cancer”) report a significant growth in prostate cancer screening in France between 2005 and 2008:  with more persons screened, more often, at a younger age.
  • Palesh et al. (“A phase III randomized prospective trial of the effect of psychotherapy on distress in 287 prostate cancer patients: a URCC CCOP study“) report data from a Phase III randomized trial showing that group psychotherapy does not improve distress among men with prostate cancer.
  • Perez et al. (“Results from the first phase I clinical study of the novel Ii-Key/HER2/neu[776-790] hybrid peptide vaccine in patients with prostate cancer”) report that the AE37 vaccine is safe, well tolerated, and capable of eliciting potent and specific immunologic responses in prostate cancer patients.
  • Lubaroff et al. (“A phase II trial of an adenovirus/PSA vaccine for prostate cancer”) will update results of their Phase II trial of an adenovirus/PSA immunotherapeutic “vaccine” trial.
  • Lowrance et al. (“Locally advanced prostate cancer: a population-based study of treatment patterns and predictors”) have reviewed data on changing patterns of treatment of men diagnosed with T3 and T4 prostate cancer, noting the increasing evidence in favor of multi-modality treatment for such patients.
  • Noguchi et al. (“A randomized trial of personalized peptide vaccine [PPV] plus low-dose estramustine [EMP] versus full-dose EMP in patients with hormone-refractory prostate cancer”) report promising early results of the combination of a personalized peptide vaccine + low-dose estramustine phosphate vs. high-dose estamustine phosphate in patients with HRPC.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 1,175 other followers